Figure 1From: Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study Prevalence of cutaneous adverse events per DMT as reported by dermatologists (black bars), by patients themselves (white bars), and by the treating neurologists (grey bars). Back to article page